Alex Mowat Prize

PURPOSE AND SCOPE

This is a prize for the best paper/presentation in the field of Hepatology at the ESPGHAN Annual Meeting.

Specification: Awards will be given to the best abstracts presented at the ESPGHAN Annual Meeting and will be presented to the prize winner at the Closing Ceremony.
 
Amount: EUR 2.500,00 per prize

ELIGIBILITY

  • Presentation of an abstract at the ESPGHAN Annual Meeting
  • Prizes are open to both Members and Non-Members

SELECTION PROCESS AND CRITERIA

Selection Process:

1/ Identification by the ESPGHAN Scientific Committee, of 15 highest scored abstracts to be presented at the Annual Meeting (AM)
2/ Review of highest scored abstract is carried out by the respective Committees during the AM
3/ The chair or the secretary of the relevant Committee reports to Council and the ESPGHAN Office on the best abstract after the morning sessions on the final day (Saturday) of the AM at the latest.

Selection Criteria:

The respective Committees will assess the abstracts against the following criteria:

  • clinical/scientific input
  • methods
  • results
  • conclusions
  • presentation

RECOGNITION OF PRIZE WINNERS

Winners will be announced and presented with a certificate at the closing ceremony of the respective Annual Meeting. 
 

ALEX MOWAT PRIZE WINNERS

2019

Dominique  Lenz: Biallelic mutations in RINT1 - a new cause of recurrent acute liver failure with onset in infancy and dysostosis multiplex

2018

Louise Coppin: The thrombogenic risk induced by intraportal infusion of Adult Derived Human Liver Stem/Mesenchymal Cells in Wistar rats can be controlled

2017

Orith Waisbourd-Zinman: Biliatresone, a toxin model of biliary atresia in animals, causes reversible damage to extra hepatic bile ducts, and its toxicity is related to Rhou and Soux17

2016

Philippa Prentice: Human milk short chain fatty acid composition is associated with infancy adiposity outcomes

2015

Kai Hensel: Hepatitis B Virus-Induced Histone Hypoacetylation in Non-Transformed Murine Hepatocytes is Associated with Upregulated Sirtuin

2014

Anne-Sophie Brunet: Exchangeable copper a new promising biomarker for monitoring of wilson’s disease

2013

C.Klemann: Neutralisation of interleukin-17 disrupts disease progression in experimental biliary atresia: a new therapeuptic approach?

2012

Peter Witters: Continuity of inflammation leads to portal branch venopathy and non-chirrhotic portal hypertension in cystic fibrosis

2011

Imeke Goldschmidt: Limitations of transient liver elastography in children

2010

Emer Fitzpatrick: Non-invasive biomarkers and paediatric nafld: new methods to predict disease and stratify severity

2009

Anshu Srivastava: In vivo proton mri spectroscopy changes in children with extra hepatic portal vein obstruction

2007

Fillipos Sagias

2005

Stephenne et al. : Chimeric engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency
Shared with:
Staplebroek J et al : Nasal biliary drainage induces remission in benign recurrent intrahepatic cholestasis

2004

Gissen P, Johnson CA, Stapelbroek J, McKeirnan PJ, McClean P, Klomp LWZ, Houwen R, Kelly DA, Maher ER. : A locus for arthrogryposis, renal dysfunction and cholestasis symdrome maps to chromosome 15q
Shared with
Compeyrot - Lacassagne S, Lacaille F, Fischer A. : Incidence, risk factors and evolution of veno-occlusive disease in children after bone marrow transplantation